Trinity Biotech plc
TRIB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $62 | $57 | $63 | $81 |
| % Growth | 8.3% | -9.1% | -23% | – |
| Cost of Goods Sold | $40 | $37 | $53 | $55 |
| Gross Profit | $21 | $19 | $22 | $33 |
| % Margin | 34.8% | 34.2% | 35.3% | 41.2% |
| R&D Expenses | $5 | $4 | $4 | $4 |
| G&A Expenses | $0 | $0 | $0 | $25 |
| SG&A Expenses | $29 | $31 | $29 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $9 | $11 | -$0 | $0 |
| Operating Expenses | $43 | $46 | $33 | $30 |
| Operating Income | -$21 | -$27 | -$15 | $4 |
| % Margin | -34.4% | -47.6% | -24.4% | 4.9% |
| Other Income/Exp. Net | -$10 | -$10 | -$24 | -$6 |
| Pre-Tax Income | -$31 | -$37 | -$44 | -$2 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$32 | -$24 | -$41 | $1 |
| % Margin | -51.6% | -42.3% | -65.6% | 1.1% |
| EPS | -1.77 | -3.2 | -6 | 0.21 |
| % Growth | 44.7% | 46.7% | -2,957.1% | – |
| EPS Diluted | -1.77 | -3.2 | -5.2 | 0.16 |
| Weighted Avg Shares Out | 18 | 8 | 7 | 4 |
| Weighted Avg Shares Out Dil | 18 | 8 | 8 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $1 |
| Interest Expense | $10 | $10 | $25 | $7 |
| Depreciation & Amortization | $2 | $2 | $2 | $3 |
| EBITDA | -$17 | -$24 | -$17 | $11 |
| % Margin | -27.5% | -42.4% | -26.7% | 13.1% |